BCRX vs CSL: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
CSL is the larger of the two ($14.90B market cap): the incumbent the market prices for continued execution (16.01x forward earnings, beta 0.78). BCRX is the smaller challenger ($1.87B), cheaper on forward earnings (8.51x): more room to run, but more to prove. If you believe CSL earns its premium (16.01x forward earnings, so the market expects more from it), CSL fits. If you believe in paying less for profit, BCRX fits at 8.51x.
BCRX vs CSL: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | BCRX | CSL | What it tells you |
|---|---|---|---|
| Market cap | $1.87B | $14.90B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 8.51 | 16.01 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.51 | 0.78 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 21% of range | 65% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Reading it: BCRX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how BCRX and CSL affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BCRX and CSL share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BCRX and CSL exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does BioCryst Pharmaceuticals (BCRX) do?
BioCryst Pharmaceuticals develops and commercializes medicines for rare diseases, with a near-total focus on hereditary angioedema (HAE), a genetic disorder that causes unpredictable and sometimes life-threatening swelling attacks. Its lead product is ORLADEYO (berotralstat), the first oral, once-daily plasma kallikrein inhibitor approved to prevent HAE attacks, which competes against injectable and infused prophylaxis therapies. The company also markets RAPIVAB (peramivir) for influenza and, through its January 2026 acquisition of Astria Therapeutics, added navenibart (formerly STAR-0215), a long-acting injectable antibody in Phase 3 for HAE prophylaxis, plus an early-stage ocular program (avoralstat).
What does Carlisle Companies Incorporated (CSL) do?
Carlisle Companies Incorporated (NYSE: CSL) is a diversified manufacturer that, after years of portfolio reshaping, has become a focused supplier of building-envelope products that make commercial and residential buildings more energy efficient. It operates through two segments: Carlisle Construction Materials (CCM), which makes single-ply roofing membranes (EPDM rubber, TPO, and PVC), polyiso insulation, and metal roofing and wall systems, and Carlisle Weatherproofing Technologies (CWT), which makes waterproofing, air and vapor barriers, sealants, spray polyurethane foam, coatings, and related moisture-protection products. The company earns most of its revenue from commercial construction, and within that, a large share comes from re-roofing (replacing aging roofs), which is more stable than new construction because roofs wear out on a predictable cycle regardless of the economy.
BCRX vs CSL: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- BCRX drivers: ORLADEYO revenue growth and operating leverage; Navenibart and the Astria pipeline bet.
- CSL drivers: Commercial re-roofing replacement cycle; Margin expansion and pure-play focus.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: BioCryst is a concentrated single-franchise story: the large majority of revenue comes from ORLADEYO, so any competitive share loss, pricing pressure, or safety signal would hit hard; reported ORLADEYO growth of only about 1% in Q2 2026 shows how quickly the trajectory can flatten. For CSL, carlisle's end markets are cyclical: commercial and residential construction activity is sensitive to interest rates, credit availability, and the broader economy, and a downturn in construction spending would pressure volumes.
BCRX or CSL: which should you pick?
If the story you believe is BCRX's (ORLADEYO revenue growth and operating leverage), BCRX is the more direct way to own it; if it is CSL's (Commercial re-roofing replacement cycle), CSL is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BCRX and CSL guides.
BCRX vs CSL: the full fundamentals
BCRX. BioCryst trades on the strength and durability of its ORLADEYO franchise rather than on trailing GAAP earnings, which still show a net loss of about $360 million because of the roughly $698 million one-time acquired-IPR&D charge from the Astria deal in Q1 2026. Trailing revenue near $962 million is inflated by one-time licensing items, so the guided $625 to $645 million of 2026 revenue is the cleaner base, and analysts expect about $736 million in 2027. At $7.28 the stock trades near 8.5x forward earnings and about 5x EV/EBITDA, while the 11 analysts tracked by Yahoo Finance carry a mean target near $20.
CSL. Carlisle now trades near 22x trailing earnings and about 16x forward, up from 19x and 14x in October as the shares rose about 11% over the past month despite a Q3 margin squeeze. Investors still focus on adjusted EBITDA margin (about 23.8% in Q3), free cash flow (about $582 million trailing) and the pace of buybacks more than raw revenue growth, which swings with weather and construction cycles. Analysts expect about $21.04 of EPS for 2026 and about $24.07 for 2027, with fourth-quarter consensus near $4.45 on about $1.22 billion of revenue.
Headline figures (approximate, November 2026): BCRX shows revenue (ttm) ~$962M (includes one-time licensing revenue), q3 2026 total revenue ~$180M (up ~13% YoY; ~$166M estimate), q3 2026 eps Adjusted $0.27 vs $0.12 estimate; GAAP $0.14 diluted, 2026 revenue guidance ~$625M to $645M, upper end expected; CSL shows revenue (ttm) ~$5.2 billion, revenue growth (q3 2026, yoy) ~8.6% (organic ~8.8%), q3 2026 adjusted eps ~$5.92 vs ~$5.90 consensus, margins (ttm gross / operating / net) ~35% / ~20% / ~14%.
The bottom line: BCRX vs CSL
BCRX and CSL are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined BCRX and CSL exposure against your real portfolio. It is not an investment adviser.
Wondering how BCRX or CSL fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about BioCryst Pharmaceuticals
Ask Walnut's AI anything about BCRX and see how it fits what you own.
FAQ
What is the difference between BCRX and CSL?
+
BioCryst Pharmaceuticals develops and commercializes medicines for rare diseases, with a near-total focus on hereditary angioedema (HAE), a genetic disorder that causes unpredictable and sometimes life-threatening swelling attacks. Carlisle Companies Incorporated (NYSE: CSL) is a diversified manufacturer that, after years of portfolio reshaping, has become a focused supplier of building-envelope products that make commercial and residential buildings more energy efficient. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is BCRX or CSL the better stock?
+
Neither is universally better. CSL is the larger incumbent; BCRX is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, BCRX or CSL?
+
On forward P/E (as of November 2026), BCRX trades at 8.51x and CSL at 16.01x, so BCRX is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both BCRX and CSL?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of BCRX vs CSL?
+
BCRX: BioCryst is a concentrated single-franchise story: the large majority of revenue comes from ORLADEYO, so any competitive share loss, pricing pressure, or safety signal would hit hard; reported ORLADEYO growth of only about 1% in Q2 2026 shows how quickly the trajectory can flatten. The HAE prophylaxis market is crowding fast, with Takeda's Takhzyro, CSL's Andembry, and Ionis's Dawnzera (donidalorsen) all competing for the same patients on convenience and dosing frequency. The Astria acquisition added debt (including a Blackstone financing facility; total debt was about $828 million against about $375 million of cash as of September 30, 2026) and share dilution, and navenibart still carries clinical and regulatory risk with Phase 3 data expected in the third quarter of 2027 and a filing only around the end of 2027. GAAP results have been distorted by large non-cash charges, and the company has a history of operating losses, so profitability at the GAAP level is not yet proven. As a biotech, it remains sensitive to trial outcomes, regulatory decisions, and financing conditions. The share price has also fallen about 26% in three months despite beats, and Wedbush trimmed its target to $17 from $18 on November 4, 2026, so sentiment can move independently of reported results. CSL: Carlisle's end markets are cyclical: commercial and residential construction activity is sensitive to interest rates, credit availability, and the broader economy, and a downturn in construction spending would pressure volumes. Revenue can swing on weather, as seen in Q1 2026 when unfavorable winter conditions limited contractors' days on the roof and helped push revenue down about 4% year over year. The business is exposed to raw-material and energy cost inflation (chemicals, membranes, insulation feedstocks), which in Q3 2026 cut operating margin to about 20% from 21.8% and delayed price-cost parity by a quarter, and to destocking or restocking cycles in its distribution channel that can amplify demand swings. Competition in single-ply roofing is intense, with large rivals such as Holcim (owner of Firestone and Duro-Last), GAF, and Johns Manville. Finally, much of Carlisle's growth story depends on continued margin expansion and disciplined capital allocation, so any slippage in pricing power or a misstep in M&A could weigh on the shares. The balance sheet carries about $2.9 billion of debt against about $547 million of cash, and debt-funded buybacks leave less cushion if a construction slowdown arrives; the PermaTherm deal adds integration risk, and the shares have also traded as low as about $295 in the past year.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BCRX or CSL; figures are approximate and dated (as of November 2026). Verify current data before investing.